Epstein-Barr Virus, Recombinant, Early Antigen (HHV-4, EBV, EBV-Ea)
Catalog No : USB-208880
531.05€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Epstein-Barr Virus, Recombinant, Early Antigen (HHV-4, EBV, EBV-Ea) | ||
|---|---|---|---|
| Catalog No | USB-208880 | ||
| Supplier’s Catalog No | 208880 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant, E. coli | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 35.5 | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | ~95% (10% PAGE, coomassie staining) | ||
| Form | Supplied as a liquid in 50mM Tris-HCl, 10mM glutation, 60mM sodium chloride, 0.5% sarcosyl, 50% glycerol. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | ~95% (10% PAGE, coomassie staining) | ||
| Description | The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virus of the herpes family (which includes Herpes simplex virus and Cytomegalovirus. On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expression which can be broadly categorized as being lytic cycle or latent cycle. The lytic cycle or productive infection results in staged expression of a host of viral proteins with the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cellas EBV virions are produced by budding from the infected cell. The latent cycle (lysogenic) programs are those that do not result in production of virions. A very limited, distinct set of viral proteins are produced during latent cycle infection. These include Epstein-Barr nuclear antigen (EBNA)-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-leader protein (EBNA-LP) and latent membrane proteins (LMP)-1, LMP-2A and LMP-2B and the Epstein-Barr encoded RNAs (EBERs). Source: Recombinant protein corresponding to the HHV-4 Early Antigen C-terminus regions, aa306-390, expressed in E. coli. Specificity: Immunoreactive with sera of EBV-infected individuals. Molecular Weight: ~35.5kD Applications: Suitable for use in ELISA, Western Blot and as an Antigen for detection of HHV-4 (EBV) with minimal specificity problems. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. | ||
Product Details
© 2020 Imugex All Rights Reserved